Literature DB >> 30170734

Pathophysiology of convulsive status epilepticus.

Iván Sánchez Fernández1, Howard P Goodkin2, Rod C Scott3.   

Abstract

PURPOSE: To summarize the pathophysiology of convulsive status epilepticus (SE) with a focus on practical implications for treatment.
METHOD: Narrative review of the medical literature on the pathophysiology of convulsive SE. We considered both animal models of SE and clinical studies.
RESULTS: Convulsive SE is an emergency in which prolonged convulsive seizures are associated with cardiorespiratory instability, hypoxia, hypoglycemia, and hyperthermia. Supportive treatment helps correct these physiological imbalances. When treatment is delayed, the ability of first line seizure suppressing medications to terminate the seizure can be reduced. Animal studies have suggested that GABAA receptor trafficking may contribute to the failure of the first line therapies and that NMDA receptor antagonists such as ketamine may become more effective as seizures last longer. Potential strategies to take advantage of these changes in pathophysiology include a rapid escalation from benzodiazepines to non-benzodiazepine antiepileptic drugs (AEDs), early polytherapy and use of NMDA antagonists such as ketamine for refractory convulsive SE. Despite the importance of a timely treatment of convulsive SE, major treatment delays are frequent in clinical practice. Policies to improve time to treatment, especially in convulsive SE that starts outside the hospital, may improve response to treatment and convulsive SE outcomes.
CONCLUSIONS: Convulsive SE is a time-sensitive emergency in which the underlying pathophysiology may provide targets for improving treatment strategies. A timely transition from benzodiazepines to other AEDs may help reduce treatment resistance in convulsive SE.
Copyright © 2018 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epilepsy; Neurotransmission; Pathophysiology; Pediatric; Status epilepticus

Mesh:

Substances:

Year:  2018        PMID: 30170734      PMCID: PMC6506391          DOI: 10.1016/j.seizure.2018.08.002

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  58 in total

1.  Constitutive endocytosis of GABAA receptors by an association with the adaptin AP2 complex modulates inhibitory synaptic currents in hippocampal neurons.

Authors:  J T Kittler; P Delmas; J N Jovanovic; D A Brown; T G Smart; S J Moss
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

2.  Changes in cerebral dynamics associated with seizures.

Authors:  P T WHITE; P GRANT; J MOSIER; A CRAIG
Journal:  Neurology       Date:  1961-04       Impact factor: 9.910

3.  Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR).

Authors:  A Coeytaux; P Jallon; B Galobardes; A Morabia
Journal:  Neurology       Date:  2000-09-12       Impact factor: 9.910

4.  N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat.

Authors:  A M Mazarati; C G Wasterlain
Journal:  Neurosci Lett       Date:  1999-04-23       Impact factor: 3.046

5.  Ketamine controls prolonged status epilepticus.

Authors:  D J Borris; E H Bertram; J Kapur
Journal:  Epilepsy Res       Date:  2000-12       Impact factor: 3.045

6.  Status epilepticus increases the intracellular accumulation of GABAA receptors.

Authors:  Howard P Goodkin; Jwu-Lai Yeh; Jaideep Kapur
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.167

7.  Incidence and mortality of generalized convulsive status epilepticus in California.

Authors:  Y W Wu; D W Shek; P A Garcia; S Zhao; S C Johnston
Journal:  Neurology       Date:  2002-04-09       Impact factor: 9.910

8.  Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus.

Authors:  Dorothy M Jones; Nadia Esmaeil; Stephen Maren; Robert L Macdonald
Journal:  Epilepsy Res       Date:  2002-08       Impact factor: 3.045

9.  Time to treatment in prolonged seizure episodes.

Authors:  John M Pellock; Anthony Marmarou; Robert DeLorenzo
Journal:  Epilepsy Behav       Date:  2004-04       Impact factor: 2.937

10.  Incidence and short-term prognosis of status epilepticus in adults in Bologna, Italy.

Authors:  Luca Vignatelli; Caterina Tonon; Roberto D'Alessandro
Journal:  Epilepsia       Date:  2003-07       Impact factor: 5.864

View more
  5 in total

1.  Factors Associated With Prolonged Length of Stay in Patients Hospitalized With Generalized Convulsive Status Epilepticus in the United States.

Authors:  Alain Lekoubou; Kunal Debroy; Kinfe G Bishu; Bruce Ovbiagele
Journal:  Neurohospitalist       Date:  2021-04-09

2.  Open-label clinical trial of rectally administered levetiracetam as supplemental treatment in dogs with cluster seizures.

Authors:  Giulia Cagnotti; Rosangela Odore; Iride Bertone; Cristiano Corona; Elena Dappiano; Giulia Gardini; Barbara Iulini; Claudio Bellino; Antonio D'Angelo
Journal:  J Vet Intern Med       Date:  2019-06-20       Impact factor: 3.333

Review 3.  Pharmacotherapy for Pediatric Convulsive Status Epilepticus.

Authors:  Avantika Singh; Coral M Stredny; Tobias Loddenkemper
Journal:  CNS Drugs       Date:  2020-01       Impact factor: 5.749

4.  Propensity for seizure-related cortical laminar necrosis in hepatic encephalopathy.

Authors:  James Peters; Nirosen Vijiaratnam; Joseph Z W Wong; Sonia Jitpiriyaroj; Ronil V Chandra; Peter A Kempster
Journal:  Epilepsy Behav Rep       Date:  2019-11-15

Review 5.  Roles of N-Methyl-D-Aspartate Receptors (NMDARs) in Epilepsy.

Authors:  Shuang Chen; Da Xu; Liu Fan; Zhi Fang; Xiufeng Wang; Man Li
Journal:  Front Mol Neurosci       Date:  2022-01-07       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.